Results 107 patients received 3wC (n=31) or 3wCP (n=76, 2 receiving 3wC with weekly paclitaxel). Patients treated with 3wC rather than 3wCP were older ((median age 83 vs. 75 (p<0.001)) with more comorbidities (median CCI 4 vs. 3 (p<0.001)). Treatment was discontinued for 4 of the 31 (13%) 3wC patients and 6 of the 76 (8%) patients who received 3wCP, with death and disease progression the most common reasons for discontinuation respectively, although the difference in discontinuation rate was not significant (p>0.05). Dose reductions occurred in 16% (5/31) of patients who received 3wC and 57% (43/76) of patients treated with 3wCP, most commonly due to haematological toxicity and peripheral neuropathy respectively.

Conclusion In spite of the limitations of our retrospective analysis, 3wCP appears as feasible as 3wC monotherapy for frail ≥70 yo FIGO stage III/IV OC patients, in keeping with the EWOC-1 data, and should be considered in this cohort given that it has been shown to achieve better survival outcomes. Toxicity profiles differ and dose reductions may be required in each treatment arm.

Abstract 2022-RA-1312-ESGO Figure 1 Overview of toxicities leading to dose reduction and treatment discontinuation in 3wC and 3wC cohorts

Introduction/Background Ovarian cancer is a common malignancy associated with poor outcomes. The tumour microenvironment (TME) has been shown to be important in tumorigenesis and prognosis. Tumour associated macrophages (TAM) are the most abundant type of immune cells in TME. Dependent on stimuli, TAM may become anti-tumorigenic M1-type or pro-tumorigenic M2-type (CD163+). The significance of TAM in young women with ovarian tumours has not been previously established. We aimed to characterise the TAM in the TME of both borderline (BOT) and malignant ovarian tumours in young women.

Methodology Patients under the age of 50, who underwent surgical management for borderline or malignant ovarian tumours at a large tertiary UK institution in 2010–2015 were included. Full clinical, pathological and outcome data were collected. Primary tumour sections were reviewed and immunohistochemically stained, intra-tumoral and stromal CD68+/CD163+ cells were scored following the International Immuno-Oncology Biomarker Working Group guidelines. Percentage stromal infiltration was calculated in relation to the stromal area and mean cell count and percentage infiltration per case calculated.

Results 57 patients; 23 with BOT and 24 cancers, were included. The mean age was 38 years, and the commonest histological type was serous carcinoma (n=21). Intratumoral expressions in platinum resistant patients in high grade serous ovarian cancer pathology group who were resistant to platinum therapy estrogen receptor was found to be positive in all 16 patients.

Conclusion High positive staining of MUC1 was determined in low grade serous ovarian cancer and clear cell carcinoma group patients. The higher estrogen-progesterone receptor expressions in platinum resistant patients in high grade serous ovarian cancer group, the detection of HER2neu positivity in half of the population in the mucinous carcinoma group is an important result of this study. For targeted therapy results should be taken into account in these epithelial ovarian cancers which are difficult to manage.

Abstract 2022-RA-1318-ESGO IMMUNOHISTOCHEMICAL PROFILING OF MACROPHAGE SUBTYPES IN THE MICROENVIRONMENT OF OVARIAN TUMOURS IN YOUNG WOMEN

1Emily Miranda Fox, 2Kirstie Rice, 3Anjali Bhatnagar, 4Daniel Kearns, 4Fedor Berditchewski, 1Abi Pratap Shukla, 5Alaa El-Ghobashy, Obstetrics and Gynaecology, Worcestershire Acute Hospitals NHS Trust, Worcester, UK; 6Pathology, The Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK; 7Cellular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK; 8Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; 9Gynaecological Oncology, Obstetrics and Gynaecology, The Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.

Int J Gynecol Cancer: first published as 10.1136/ijgc-2022-ESGO.688 on 20 October 2022. Downloaded from http://ijgc.bmj.com/ on September 15, 2023 by guest. Protected by copyright.